TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Tyra Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$19.34+0.82 (+4.43%)
Close on Oct 19, 2026
- Market cap
- $1.28B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.84 (+33.38%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.28B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.61
- Dividend yield
- –
- Free cash flow yield
- -8.61%
Fundamentals
- Net income
- -$148.57M
- EPS, diluted
- -$2.40
- Free cash flow
- -$109.90M
- Book value per share
- $5.36
- Diluted shares
- 66M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$160.46M
Net income
-$148.57M
EPS, diluted
-$2.40
Free cash flow
-$109.90M
Reported periodTrailing twelve months